FindTrial
Sign In

Study on the mechanism of induction of F VIII immune tolerance by maternal microchimerism in severe hemophilia A

Study on the mechanism of induction of F VIII immune tolerance by maternal microchimerism in severe hemophilia A

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500108384
Enrollment
Unknown
Registered
2025-08-29
Start date
2025-09-01
Completion date
Unknown
Last updated
2025-09-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemophilia A

Interventions

Observation group:None

Sponsors

Beijing Children's Hospital Affiliated to Capital Medical University
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
No minimum to 6 Years

Inclusion criteria

Inclusion criteria: 1.Hemophilia A severe (FVIII: C<1%); 2. Age<6 years old; 3. Have not received FVIII replacement therapy

Exclusion criteria

Exclusion criteria: 1. Patients with chronic diseases (such as kidney, rheumatism, immunology, cardiovascular and cerebrovascular diseases, other blood tumor diseases besides hemophilia A, etc.); 2. Use non coagulation factor drugs as substitutes for treatment, such as pembrolizumab.

Design outcomes

Primary

MeasureTime frame
FVIII inhibitor;—

Countries

China

Contacts

Public ContactLi Zekun; Wu Runhui

Beijing Children's Hospital Affiliated to Capital Medical University

zekunli@foxmail.com+86 188 0111 9973

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026